|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
97,871,000 |
Market
Cap: |
902.37(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$6.66 - $22.03 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : 20.2 |
Insider 6 Months : 20.2 |
Insider 3/6 Months : 40.8 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile 89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Co.'s primary product candidate, pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia. FGF21 is a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism. FGF21 analogs represent a class of drugs to treat NASH, because they not only address the liver manifestations, but also have an effect on the multiple co-morbidities that worsen NASH.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
1,350,000 |
1,350,000 |
1,350,000 |
7,862,717 |
Total Buy Value |
$20,722,500 |
$20,722,500 |
$20,722,500 |
$80,687,796 |
Total People Bought |
1 |
1 |
1 |
2 |
Total Buy Transactions |
1 |
1 |
1 |
5 |
Total Shares Sold |
57,195 |
107,195 |
154,628 |
206,908 |
Total Sell Value |
$623,326 |
$1,183,326 |
$2,078,063 |
$2,842,845 |
Total People Sold |
1 |
1 |
4 |
5 |
Total Sell Transactions |
2 |
3 |
7 |
15 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Shah Rajeev M. |
Director |
|
2022-07-01 |
4 |
B |
$3.55 |
$9,999,995 |
I/I |
2,816,900 |
7,782,669 |
2.25 |
163% |
|
Hayden Michael R |
|
|
2022-04-25 |
4 |
B |
$2.67 |
$26,700 |
I/I |
10,000 |
103,978 |
0.01 |
70% |
|
Hayden Michael R |
|
|
2022-04-07 |
4 |
B |
$3.48 |
$34,750 |
I/I |
10,000 |
93,978 |
0.01 |
51% |
|
Hayden Michael R |
|
|
2022-03-30 |
4 |
B |
$3.62 |
$22,625 |
I/I |
6,250 |
83,978 |
0.01 |
16% |
|
Palekar Rohan |
Chief Executive Officer |
|
2022-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
54,200 |
100,045 |
|
- |
|
Martins Ryan |
Chief Financial Officer |
|
2022-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
23,500 |
|
- |
|
Waisbourd Ram |
See Remarks |
|
2022-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
8,750 |
8,750 |
|
- |
|
Le-Nguyen Quoc |
See Remarks |
|
2022-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
32,500 |
|
- |
|
Mansbach Harry H |
Chief Medical Officer |
|
2022-02-17 |
4 |
A |
$0.00 |
$0 |
D/D |
22,500 |
32,500 |
|
- |
|
Le-Nguyen Quoc |
See Remarks |
|
2022-02-05 |
4 |
D |
$5.23 |
$7,128 |
D/D |
(1,363) |
31,137 |
|
- |
|
Martins Ryan |
Chief Financial Officer |
|
2022-02-05 |
4 |
D |
$5.23 |
$5,345 |
D/D |
(1,022) |
22,478 |
|
- |
|
Mansbach Harry H |
Chief Medical Officer |
|
2022-02-05 |
4 |
D |
$5.23 |
$7,128 |
D/D |
(1,363) |
31,137 |
|
- |
|
Palekar Rohan |
Chief Executive Officer |
|
2022-02-05 |
4 |
D |
$5.23 |
$21,380 |
D/D |
(4,088) |
95,957 |
|
- |
|
Waisbourd Ram |
See Remarks |
|
2022-02-01 |
4 |
AS |
$5.70 |
$39,900 |
D/D |
(7,000) |
0 |
|
-38% |
|
Waisbourd Ram |
See Remarks |
|
2022-02-01 |
4 |
OE |
$1.93 |
$13,510 |
D/D |
7,000 |
7,000 |
|
- |
|
Palekar Rohan |
Chief Executive Officer |
|
2022-01-28 |
4 |
B |
$6.14 |
$15,350 |
D/D |
2,500 |
45,845 |
2.81 |
-35% |
|
Palekar Rohan |
Chief Executive Officer |
|
2022-01-27 |
4 |
B |
$7.50 |
$37,500 |
D/D |
5,000 |
43,345 |
2.81 |
-40% |
|
Orbimed Israel Gp Ii, L.p. |
10% Owner |
|
2022-01-26 |
4 |
S |
$8.38 |
$180,019 |
I/I |
(21,482) |
1,829,436 |
|
51% |
|
Orbimed Israel Gp Ii, L.p. |
10% Owner |
|
2022-01-25 |
4 |
S |
$8.40 |
$412,364 |
I/I |
(49,091) |
1,840,176 |
|
55% |
|
Waisbourd Ram |
See Remarks |
|
2021-12-16 |
4 |
AS |
$11.48 |
$80,360 |
D/D |
(7,000) |
0 |
|
-79% |
|
Waisbourd Ram |
See Remarks |
|
2021-12-16 |
4 |
OE |
$1.93 |
$13,510 |
D/D |
7,000 |
7,000 |
|
- |
|
Waisbourd Ram |
See Remarks |
|
2021-11-16 |
4 |
AS |
$16.49 |
$115,430 |
D/D |
(7,000) |
0 |
|
-78% |
|
Waisbourd Ram |
See Remarks |
|
2021-11-16 |
4 |
OE |
$1.93 |
$13,510 |
D/D |
7,000 |
7,000 |
|
- |
|
Waisbourd Ram |
See Remarks |
|
2021-10-18 |
4 |
AS |
$17.49 |
$122,430 |
D/D |
(7,000) |
0 |
|
-74% |
|
Waisbourd Ram |
See Remarks |
|
2021-10-18 |
4 |
OE |
$1.93 |
$13,510 |
D/D |
7,000 |
7,000 |
|
- |
|
190 Records found
|
|
Page 5 of 8 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|